



# HHS Public Access

Author manuscript

*Cancer Prev Res (Phila)*. Author manuscript; available in PMC 2022 June 30.

Published in final edited form as:

*Cancer Prev Res (Phila)*. 2022 June 02; 15(6): 415. doi:10.1158/1940-6207.CAPR-22-0200.

## Retraction: HSP90 Inhibitors Suppress Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and DNA Adduct Formation

Duncan Hughes,

Joseph B. Guttenplan,

Craig B. Marcus,

Kotha Subbaramaiah,

Andrew J. Dannenberg

---

This article (1) has been retracted at the request of the authors. There was evidence of data falsification or fabrication found in two figures. In Fig. 2,  $\beta$ -actin controls for MSK-Leuk1 and KYSE450 cells treated with Celestrol, the  $\beta$ -actin band in the KYSE450 cells appears to have been duplicated and flipped horizontally. In Fig. 3,  $\beta$ -actin control for CYP1A1/KYSE450 and  $\beta$ -actin control for CYP1B1/MSK-Leuk1 appear to be duplicates of one another. A copy of this Retraction Notice was sent to the last known e-mail addresses for the 5 authors. Four authors (Duncan Hughes, Craig B. Marcus, Kotha Subbaramaiah, and Andrew J. Dannenberg) agreed to the retraction; one author (Joseph B. Guttenplan) did not respond. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

### Reference

1. Hughes D, Guttenplan JB, Marcus CB, Subbaramaiah K, Dannenberg AJ. HSP90 inhibitors suppress Aryl hydrocarbon receptor mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. *Cancer Prev Res* 2008;1:485–93.